8-K: Owlet Announces Strong Fourth Quarter and Full Year 2024 Results, Exceeding Guidance

Owlet reports a 45% increase in full-year revenue and significant improvements in gross margin and adjusted EBITDA, marking its strongest financial performance in company history.

Summary

• Owlet, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Q4 revenue was $20.5 million, a 37% increase compared to Q4 2023 when excluding the impact of an Amazon distribution partner transition.
• The Q4 gross margin was 53.5%, up 650 basis points from Q4 2023.
• The Q4 net loss was $(9.1) million, compared to $(6.9) million in Q4 2023.
• The Q4 adjusted EBITDA was $0.5 million, improving $1.2 million compared to Q4 2023.
• Full-year 2024 revenue was $78.1 million, up 45% from 2023.
• The full-year 2024 gross margin was 50.4%, up 850 basis points from 2023.
• The full-year 2024 net loss was $(12.5) million, compared to $(32.9) million in 2023.
• The full-year 2024 adjusted EBITDA was $(2.0) million, improving $14.3 million compared to 2023.
• For the full year 2025, Owlet expects revenue in the range of $88 million to $92 million and gross margins in the range of 50% to 52%, striving for adjusted EBITDA profitability.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with significant improvements in revenue, gross margin, and reduced net losses. The launch of Owlet360 and the focus on achieving profitability in 2025 contribute to a favorable sentiment.

Positives

• Owlet experienced a 45% increase in full-year revenue, reaching $78.1 million.
• The company's gross margin improved significantly, reaching 50.4% for the full year.
• Owlet reduced its net loss from $(32.9) million in 2023 to $(12.5) million in 2024.
• Adjusted EBITDA improved by $14.3 million year-over-year.
• The launch of Owlet360 represents a step towards becoming a comprehensive pediatric health platform.
• Owlet anticipates revenue between $88 million and $92 million for 2025.
• The company is aiming for adjusted EBITDA profitability in 2025.

Negatives

• Owlet reported a net loss of $(9.1) million for Q4 2024, compared to $(6.9) million in Q4 2023.
• The company still experienced a net loss of $(12.5) million for the full year 2024.
• Adjusted EBITDA remains negative at $(2.0) million for the full year 2024, although it shows significant improvement.

Risks

• The company's ability to manage growth and competition is a risk factor.
• Regulatory pathways for Owlet's products, including FDA approvals, pose a risk.
• Reliance on mobile applications and a limited number of retailers are potential risks.
• Sourcing key materials and obtaining additional financing are also risk factors.
• Economic conditions, health epidemics, and changes in consumer spending could impact the business.
• The company's ability to protect its intellectual property and comply with privacy regulations is a risk.
• The company's limited operating history and ability to continue as a going concern is a risk.

Future Outlook

Owlet expects revenue in the range of $88 million to $92 million for the full year 2025, with gross margins between 50% and 52%, and is striving to achieve adjusted EBITDA profitability.

Management Comments

• 2024 was a pivotal year for Owlet, marking our strongest financial performance in company history, said Kurt Workman, Owlets Chief Executive Officer and Co-Founder.
• We finished the year strong with fourth quarter results that exceeded our guidance across all key metrics.
• We made significant progress in the year, including launching the first and only FDA-cleared baby monitoring device, expanding internationally, and capturing market share, positioning Owlet as a clear leader in connected pediatric health.
• We continued our momentum entering 2025, launching Owlet360, our new subscription service leveraging Owlets massive pediatric health and sleep data set to deliver personalized, actionable insights to parents.
• Looking ahead, we remain focused on scaling our core business, positioning for the large medical reimbursement opportunity, and accelerating growth in the Owlet360 subscription business.

Industry Context

Owlet's focus on connected pediatric health aligns with the growing trend of telehealth and remote patient monitoring, particularly for infants. The launch of Owlet360 positions the company to compete with other subscription-based health and wellness platforms.

Comparison to Industry Standards

• Comparable companies in the infant monitoring space include Nanit and Sense-U, though Owlet differentiates itself with its FDA-cleared medical devices.
• The gross margin improvement to 50.4% is a positive sign, bringing it closer to industry benchmarks for consumer electronics and healthcare companies.
• Achieving adjusted EBITDA profitability in 2025 would be a significant milestone, as many growth-stage companies in the connected health space prioritize revenue growth over immediate profitability.

Stakeholder Impact

• Shareholders will likely view the improved financial performance and future outlook positively.
• Employees may be encouraged by the company's growth and strategic initiatives.
• Customers can expect continued innovation and expansion of Owlet's product offerings.
• Suppliers and creditors may benefit from the company's improved financial stability.

Next Steps

• Scale the core business.
• Position for the large medical reimbursement opportunity.
• Accelerate growth in the Owlet360 subscription business.

Key Dates